美國居民不適用 XM 服務。
R
R

Regeneron

交易方向

交易者脈動

技術摘要

小時

財經新聞

Teva in talks to settle US lawsuit alleging MS drug kickbacks

Teva in talks to settle US lawsuit alleging MS drug kickbacks By Nate Raymond BOSTON, June 17 (Reuters) - Teva Pharmaceutical Industries Ltd TEVA.TA said it is in active talks to settle a U.S. Department of Justice lawsuit alleging it used charities that help cover Medicare patients' out-of-pocket drug costs as a means to pay kickbacks to boost sales of its multiple sclerosis drug Copaxone.
R
T

Regeneron Pharmaceuticals Says At 14-Months Median Follow-Up In Trial, 50% Of Patients Achieved A Complete Response Or Better, A 71% Overall Response Rate

BRIEF-Regeneron Pharmaceuticals Says At 14-Months Median Follow-Up In Trial, 50% Of Patients Achieved A Complete Response Or Better, A 71% Overall Response Rate June 16 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O : UPDATED LINVOSELTAMAB DATA SHOWCASE CONTINUED DEEPENING OF RESPONSES IN PATIENTS WITH HEAVILY PRE-TREATED MULTIPLE MYELOMA REGENER
R

Replimune rallies after $100 mln PIPE financing

BUZZ-Replimune rallies after $100 mln PIPE financing ** Shares of Replimune Group REPL.O up 8.3% at $9.55 on Thurs after biotech firm raises $100 mln in private placement ** REPL now up 6 out of past 7 sessions, racking up ~90% gain along the way ** Co early Thurs said will sell ~5.7 mln shares at $8.82 and pre-funded warrants to buy ~5.7 mln shares at $8.819/warrant in a PIPE (private investment in public equity) ** Financing led by a life-sciences focused institutional investor, with participa
R

U.S. BioNTech, Honeywell International, Klaviyo

U.S. RESEARCH ROUNDUP-BioNTech, Honeywell International, Klaviyo June 12 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Biontech, Honeywell International and Klaviyo, on Wednesday. HIGHLIGHTS * BioNTech SE BNTX.O : JP Morgan raises target price to $94 from $90 * Honeywell International Inc HON.O : HSBC raises target price to $235 from $200 * Klaviyo Inc KVYO.N : Barclays raises to overweight from equal weight * NetA
A
F
G
N
R
G
D
M

New Pharma will crowd out Big Pharma

BREAKINGVIEWS-New Pharma will crowd out Big Pharma The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan LONDON, June 11 (Reuters Breakingviews) - Big Pharma is under threat from tech-driven upstart rivals. The values of large, established players like $159 billion Pfizer PFE.N , $230 billion Novartis NOVN.S and $216 billion Roche ROG.S are converging with newer players like $121 billion Vertex Pharmaceuticals VRTX.O .
A
G
N
P
R
R
S
V

細節

熱門資產

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明